Prosecution Insights
Last updated: April 19, 2026
Application No. 16/759,475

Adamantane or Bicyclic Monoterpenoid Derivatives for Use in the Treatment of Leishmaniasis

Final Rejection §102
Filed
Apr 27, 2020
Examiner
SZNAIDMAN, MARCOS L
Art Unit
1628
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Drugabilis
OA Round
10 (Final)
37%
Grant Probability
At Risk
11-12
OA Rounds
3y 3m
To Grant
53%
With Interview

Examiner Intelligence

Grants only 37% of cases
37%
Career Allow Rate
461 granted / 1253 resolved
-23.2% vs TC avg
Strong +16% interview lift
Without
With
+16.1%
Interview Lift
resolved cases with interview
Typical timeline
3y 3m
Avg Prosecution
56 currently pending
Career history
1309
Total Applications
across all art units

Statute-Specific Performance

§101
1.8%
-38.2% vs TC avg
§103
38.8%
-1.2% vs TC avg
§102
17.2%
-22.8% vs TC avg
§112
26.7%
-13.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1253 resolved cases

Office Action

§102
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION This office action is in response to Applicant’s reply filed on January 23, 2026. Status of Claims Amendment of claims 1, 7, 9-10, 13 and 17-18 is acknowledged. Claims 1-20 are currently pending and are the subject of this office action. Claim 1-9 were withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention, there being no allowable generic or linking claim. Applicant timely traversed the restriction (election) requirement in the reply filed on July 27, 2021. Due to Applicant amendments, the previously examined species: PNG media_image1.png 326 136 media_image1.png Greyscale Is no longer encompassed by the instant claims So, the examination was expanded to the following species: PNG media_image2.png 174 344 media_image2.png Greyscale In summary, the following species are under examination: 1- PNG media_image3.png 61 136 media_image3.png Greyscale originally elected by Applicant, and 2- PNG media_image2.png 174 344 media_image2.png Greyscale expanded species. The elected species reads on claims 10, 12-13, 15-16 and 19-20. The expanded species reads on claims 10, 13-14 and 19-20. Consequently, claims 11 and 17-18 are further withdrawn since they do not read on any of the two examined species. The combined set of claims that read on one or the two species, and as a consequence, are presently under examination are claims 10, 12-16 and 19-20. Priority The present application is a 371 of PCT/EP2018/079824 filed on 10/31/2018 and claims priority to foreign application EP 17306507.9 filed on 10/31/2017. Rejections and/or Objections and Response to Arguments Rejections and/or objections not reiterated from previous office actions are hereby withdrawn. The following rejections and/or objections are either reiterated (Maintained Rejections and/or Objections) or newly applied (New Rejections and/or Objections, Necessitated by Amendment or New Rejections and/or Objections not Necessitated by Amendment). They constitute the complete set presently being applied to the instant application. Responses to Applicant’s arguments have been addressed immediately after the corresponding rejections, or in the section: Withdrawn Rejections and/or Objections, if the rejection was withdrawn. Claim Rejections - 35 USC § 102 (New Rejection Necessitated by Amendment). In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 10, 13-14 and 19-20 is/are rejected under 35 U.S.C. 102 (a) (1) as being anticipated by Zhao et. al. (Antiviral Research (2012) 96:91-99). For claims 10, 13-14 and 19-20, Zhao teaches pharmaceutical compositions comprising the compound 14 (see Scheme 1 on page 94): PNG media_image2.png 174 344 media_image2.png Greyscale The above compound corresponds to instant compound Ia, wherein: W is: PNG media_image4.png 64 64 media_image4.png Greyscale X is Hydrogen, and Ar is a 9-membered heteroaryl. Claim Objections Claims 12 and 15-16 are objected to in part as being dependent upon a rejected base claim but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims, and to recite only the elected species. Note that claims 12 and 15-16 are objected to in part herein insofar as it contains non-elected subject matter to which the prior art search has not yet been extended. That part which has been searched, however (consistent with the election of species requirement as previously discussed), would be allowable if the claim was amended in independent form including all the limitations of the base claim and any intervening claims, and to remove the currently non-elected subject matter (i.e., all the species except for the elected species). NOTE: Applicant should clarify the structural differences between groups pinanyl and isopinocamphenyl. Applicant responded that the specification discloses exemplary pinanyl and isopinocamphenyl groups in paragraph [0219] of the US 2020/0281873 publication. However, paragraph [0219} discloses the following: PNG media_image5.png 156 266 media_image5.png Greyscale PNG media_image6.png 86 240 media_image6.png Greyscale However, the first compound from the left is identical to the fourth compound, and the second compound is identical to the third compound, so there are 4 different compounds on display, which one of those is pinanyl, isopinocamphenyl or bornanyl? Conclusion No claims are allowed. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action. Correspondence Any inquiry concerning this communication or earlier communications from the examiner should be directed to MARCOS L SZNAIDMAN whose telephone number is (571)270-3498. The examiner can normally be reached on Flexing M-F 7 AM-7 PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Amy L. Clark can be reached on 571 272-1310. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /MARCOS L SZNAIDMAN/ Primary Examiner, Art Unit 1628 February 4, 2026.
Read full office action

Prosecution Timeline

Apr 27, 2020
Application Filed
Oct 24, 2021
Non-Final Rejection — §102
Jan 14, 2022
Interview Requested
Jan 18, 2022
Applicant Interview (Telephonic)
Jan 18, 2022
Examiner Interview Summary
Jan 20, 2022
Response Filed
Jan 30, 2022
Final Rejection — §102
Jun 01, 2022
Response after Non-Final Action
Jul 19, 2022
Request for Continued Examination
Jul 20, 2022
Response after Non-Final Action
Nov 06, 2022
Non-Final Rejection — §102
Feb 10, 2023
Response Filed
Mar 26, 2023
Final Rejection — §102
Jun 27, 2023
Response after Non-Final Action
Jul 10, 2023
Response after Non-Final Action
Jul 31, 2023
Request for Continued Examination
Aug 05, 2023
Response after Non-Final Action
Dec 03, 2023
Non-Final Rejection — §102
Mar 07, 2024
Response Filed
Mar 25, 2024
Final Rejection — §102
Jul 06, 2024
Response after Non-Final Action
Jul 24, 2024
Request for Continued Examination
Jul 30, 2024
Response after Non-Final Action
Nov 17, 2024
Non-Final Rejection — §102
Mar 11, 2025
Response Filed
Mar 26, 2025
Final Rejection — §102
Jul 29, 2025
Response after Non-Final Action
Aug 07, 2025
Request for Continued Examination
Aug 08, 2025
Response after Non-Final Action
Oct 20, 2025
Non-Final Rejection — §102
Jan 23, 2026
Response Filed
Feb 22, 2026
Final Rejection — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12594261
Use of Heterocyclic Derivatives with Cardiomyocyte Proliferation Activity for Treatment of Heart Diseases
2y 5m to grant Granted Apr 07, 2026
Patent 12589089
PTGDR-1 AND/OR PTGDR-2 ANTAGONISTS FOR PREVENTING AND/OR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS
2y 5m to grant Granted Mar 31, 2026
Patent 12576057
ANTIBACTERIAL AND BIOFILM FORMATION-INHIBITING COMPOSITION CONTAINING MYRISTOLEIC ACID AS ACTIVE INGREDIENT
2y 5m to grant Granted Mar 17, 2026
Patent 12570659
BICYCLIC HETEROARYL COMPOUNDS USEFUL AS IRAK4 INHIBITORS
2y 5m to grant Granted Mar 10, 2026
Patent 12558328
SOLID-FORMING TOPICAL FORMULATIONS FOR PAIN CONTROL
2y 5m to grant Granted Feb 24, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

11-12
Expected OA Rounds
37%
Grant Probability
53%
With Interview (+16.1%)
3y 3m
Median Time to Grant
High
PTA Risk
Based on 1253 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month